GW-842,166X

GW-842,166X is a drug that was developed by GlaxoSmithKline for the treatment of pain and obesity. It acts as a potent and selective agonist for the cannabinoid receptor CB2, with much lower affinity for the psychoactive CB1 receptor.

Pharmacology

GW-842,166X is a cannabinoid drug that was developed by GlaxoSmithKline. It is a potent and selective agonist for the cannabinoid receptor CB2. The CB2 receptor is primarily found in the peripheral nervous system, and its activation does not produce the psychoactive effects associated with activation of the CB1 receptor. This makes GW-842,166X a promising candidate for the treatment of pain and obesity, without the risk of psychoactive side effects.

Clinical Trials

GW-842,166X has undergone clinical trials for its potential use in the treatment of pain and obesity. However, the results of these trials have not been published, and the current status of the drug is unknown.

Potential Uses

The primary potential uses for GW-842,166X are in the treatment of pain and obesity. The drug's selective activation of the CB2 receptor could potentially provide pain relief without the psychoactive side effects associated with other cannabinoid drugs. Similarly, the drug's effects on the CB2 receptor could potentially be used to treat obesity.

See Also

• Cannabinoid receptor
• GlaxoSmithKline
• Clinical trial

‎